Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS views and news. Opt-in with us: www.register.msviewsandnews.org


~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.


Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================================================


Wednesday, May 23, 2018

Subcutaneous Ofatumumab a Safe, Effective RRMS Therapy at Low Doses, Trial Results Show


May 23rd, 2018

A formulation of ofatumumab (brand name Arzerra) to be injected under the skin (subcutaneous) was found to be safe and effective in the treatment of relapsing-remitting multiple sclerosis (RRMS), even when given at lower doses compared with Arzerra, which is administered intravenously, according to the results of a Phase 2 trial.

Subcutaneous Ofatumumab a Safe, Effective RRMS Therapy at Low Doses, Trial Results Show

Besides offering the possibility of self-administration by the patient, treatment with subcutaneous ofatumumab was seen to effectively reduce the number of brain lesions without leading to severe depletion of immune B-cells, one of the consequences of treatment with intravenous Arzerra.
The study reporting the findings is titled “Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis — The MIRROR study,” and was published in the journal Neurology.
Ofatumumab is a human monoclonal antibody targeting the CD20 molecule, which is found on the surface of B-cells or lymphocytes — key cells of the immune system also implicated in the development of multiple sclerosis.
Arzerra is currently the only approved ofatumumab formulation, indicated for the treatment of chronic lymphocytic leukemia (CLL), a blood cancer that typically develops in B-cells.
By targeting CD20, ofatumumab is able to direct the body’s immune system to fight both normal and cancerous B-cells. The medication is marketed and developed by the Danish biotech company Genmab, under a development and commercialization agreement with Novartis.

::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::


                      
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::

No comments: